Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Cold Sore Treatment Developed by Squarex Shown Effective by Immunotherapy Study

By PR Newswire | May 25, 2017

Photo credit: Metju12, Wikimedia Commons; https://commons.wikimedia.org/wiki/File:Herpes_labialis.jpg

Cold sores, which affect one in three Americans, may be effectively treated by a new immunotherapy process, as indicated by results of a 54-patient clinical trial at Massachusetts General Hospital in Boston. 

The patented therapy was developed by Squarex, LLC, of St. Paul. 

About a third of people world-wide suffer a cold sore at some time each year. The sores, which can be painful and unsightly, have stubbornly resisted effective long-term treatment, and there is no FDA-approved drug or treatment for delaying or preventing cold sore outbreaks.

While further testing is underway to validate results, researchers say the clinical trial showed that a single topical application of the Squarex drug was significantly effective in reducing cold-sore recurrence for extended periods. 

Patients in the clinical trial reported having at least six cold sore outbreaks over the previous 12 months before entering the clinical trial. After a single topical application of the drug, the time to next outbreak was tripled as compared to placebo: 40 days for the placebo group versus greater than 122 days for the group receiving the Squarex drug. 

Dr. Maria Alora-Palli of Mass. General Hospital and Harvard Medical School is lead author of the scientific paper on the Squarex study, which appears in the current JAMA Dermatology. 

Because the herpes simplex virus also causes genital herpes, Squarex President Dr. Hugh McTavish said his company would like to begin testing on the genital disease as well. 

Squarex LLC is a privately held pharmaceutical development company. 

(Source: PR Newswire)

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE